Nature Reviews Drug Discovery 17, https://doi.org/10.1038/nrd.2018.136 (2018)
In the original version of Figure 3, a dopamine D2 receptor had been positioned incorrectly and has now been moved to the correct presynaptic position on the dopaminergic neurons projecting to the basal ganglia motor circuit. In addition, the two Figure 2 citations that appeared on page 14 were incorrect and have now been changed to Figure 3.
Additional information
The online version of the original article can be found at https://doi.org/10.1038/nrd.2018.136
Rights and permissions
About this article
Cite this article
Charvin, D., Medori, R., Hauser, R. et al. Erratum: Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov 17, 844 (2018). https://doi.org/10.1038/nrd.2018.184
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.184
This article is cited by
-
Chiral metal-organic frameworks incorporating nanozymes as neuroinflammation inhibitors for managing Parkinson’s disease
Nature Communications (2023)
-
Brain regions susceptible to alpha-synuclein spreading
Molecular Psychiatry (2022)
-
Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson’s disease
Glycoconjugate Journal (2022)
-
The DJ1-Nrf2-STING axis mediates the neuroprotective effects of Withaferin A in Parkinson’s disease
Cell Death & Differentiation (2021)
